Life Science Investing Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
Life Science Investing Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
Revolve Receives Approval from the Alberta Utilities Commission for the 15.7 MW Bright Meadows Solar Project
